Email this article Objective assessment of hormonal therapy value as the risk minimization method associated with the sex hormone deficit
- Authors: Sheshukova NA1,2, Bolshakova OV1,2
-
Affiliations:
- ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
- ГБУЗ ГКБ №5, Москва
- Issue: Vol 16, No 3 (2014)
- Pages: 4-7
- Section: Articles
- URL: https://journals.rcsi.science/2079-5831/article/view/28302
- ID: 28302
Cite item
Abstract
Modern views on the issue of menopausal hormone therapy based on updated recommendations of the International Menopause Society 2013 are reviewed in the following article as well as the basic principles of hormone therapy in peri - and postmenopausal women, its benefits and possible risks. An important emphasis is made on unequal undesirable consequences from the use of combined hormonal preparations, depending on their composition and, above all, progestin component.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
N A Sheshukova
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России; ГБУЗ ГКБ №5, Москва
Email: dr.Sheshukova@mail.ru
д-р мед. наук, проф. каф. акушерства и гинекологии ИПО
O V Bolshakova
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России; ГБУЗ ГКБ №5, Москва
Email: Olesya.bolshakova.1974@mail.ru
канд. мед. наук, зав. гинекологическим отд-нием ГБУЗ ГКБ №5
References
- Byyny R.L. A Clinical Guide for the Care of Older Women, 2001.
- Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М., 2006.
- Seeger H., Mueck A.O. Effects of dydrogesterone on the vascular system. Gynecol Endocrinol 2007; 23 (Suppl. 1): 2-8.
- Collins J.A, Blake J.M. Breast cancer risk with postmenopausal hormone treatment 2005; 111: 545-60.
- Prentice R.L, Chlebowski R.T. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008; 167: 1207-16.
- Fournier A, Berrino F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 362: 419-27.
- Kanda N, Watanabe S. 17β-Estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 2004; 123: 319-28.
- Sumino H, Ichikawa S, Abe M. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004; 52: 945-9.
- Raine-Fenning N.J, Brincat M.P. Skin aging and menopause: implication for treatment. Am J Clin Dermatol 2003; 4: 371-8.
- Kwok S, Charlton-Menys V, Pemberton P et al. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. Maturitas 2006; 53: 439-46.
- Brincat M.P, Muscut Baron, Galea R. Climacteric 2005; 8: 110-23.
Supplementary files
